Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
July 24 2023 - 8:00AM
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on developing and launching the first curative
targeted cell therapies for patients with autoimmune diseases,
today announced the appointment of Shawn Tomasello to its Board of
Directors. Ms. Tomasello has over 35 years of experience in the
life sciences industry, including specific expertise in CD19-CAR T
therapy, where she most recently served as the Chief Commercial
Officer of Kite Pharma, Inc. between 2015 and 2018, leading the
worldwide commercialization effort for the CD19-CAR T cell therapy,
Yescarta®, and playing a key role in its acquisition by Gilead
Sciences, Inc. As part of her appointment to the Board of
Directors, Ms. Tomasello will become a member of the Compensation
Committee and the newly formed Science & Technology Committee.
“Shawn is a recognized biopharmaceutical leader
with a proven track record building large-scale commercial
organizations to bring transformative therapies to patients in
need, including having overseen the global commercial launch of the
leading approved CD19-CAR T cell therapy,” said Steven Nichtberger,
M.D., Chief Executive Officer and Co-founder of Cabaletta. “Shawn’s
experience in pre-launch planning, scaling and commercializing a
CD19-CAR T therapy globally will provide important additional
perspective to our Board of Directors as we continue to expand and
advance our CABA-201 development program.”
Ms. Tomasello brings over three decades of
experience in the life sciences industry and most recently served
as the Chief Commercial Officer of Kite Pharma, now part of Gilead
Sciences, where she oversaw the global commercialization of
Yescarta®, the first approved CAR-T therapy for non-Hodgkin
lymphoma. Prior to joining Kite Pharma, she was the Chief
Commercial Officer of Pharmacyclics LLC, now part of AbbVie Inc.,
where she led both commercial and medical affairs. Before that, Ms.
Tomasello held senior leadership positions at Celgene Corporation,
including President of the Americas, Hematology and Oncology, where
she led the company through five successful product launches
encompassing 11 indications and played a critical role in
acquisitions. Previously, she was National Director of Hematology
for Rituxan® at Genentech, Inc. Earlier in her career, Ms.
Tomasello held positions at Pfizer Laboratories, Miles
Pharmaceuticals, Inc. and Proctor & Gamble Company. She holds
an M.B.A. from Murray State University and a B.S. in Marketing from
the University of Cincinnati.
“I am excited to join Cabaletta’s Board of
Directors and to support the company’s vision to develop and
potentially launch the first targeted curative cell therapies for
patients with autoimmune diseases,” said Shawn Tomasello. “I look
forward to applying my decades of experience building and scaling
global commercial organizations in the life sciences industry to
bring CABA-201 closer to patients with autoimmune disease and
support development of the broader CABA™ platform.”
About Cabaletta BioCabaletta Bio
(Nasdaq: CABA) is a clinical-stage biotechnology company focused on
the discovery and development of engineered T cell therapies that
have the potential to provide a deep and durable, perhaps curative,
treatment for patients with autoimmune diseases. The CABA™ platform
encompasses two strategies: the CARTA (chimeric antigen receptor T
cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing
fully human CD19-CAR T, as the lead product candidate being
evaluated in systemic lupus erythematosus and myositis, and the
CAART (chimeric autoantibody receptor T cells) strategy, with
multiple clinical-stage candidates, including DSG3-CAART for
mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia
gravis. The expanding CABA™ platform is designed to develop
potentially curative therapies that offer deep and durable
responses for patients with a broad range of autoimmune diseases.
Cabaletta Bio’s headquarters and labs are located in Philadelphia,
PA.
Forward-Looking StatementsThis
press release contains “forward-looking statements” of Cabaletta
Bio within the meaning of the Private Securities Litigation Reform
Act of 1995, as amended, including without limitation, express or
implied statements regarding its expectations regarding: Cabaletta
Bio’s ability to grow its autoimmune-focused pipeline; its plans
around CABA-201, including its expectations for the expansion and
advancement of the CABA-201 development program and potential
launch of CABA-201; the company’s business plans and objectives,
including on a global scale; the potential curative effect of the
therapies associated with the CABATM platform; and the anticipated
contribution of the members of our board of directors, specifically
Ms. Tomasello, and our executives to our operations and
progress.
Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
of future events, and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: risks related to regulatory filings and
potential clearance; the risk that signs of biologic activity or
persistence may not inform long-term results; Cabaletta’s ability
to demonstrate sufficient evidence of safety, efficacy and
tolerability in its preclinical studies and clinical trials of
DSG3-CAART, MuSK-CAART and CABA-201; risks related to clinical
trial site activation or enrollment rates that are lower than
expected; risks related to unexpected safety or efficacy data
observed during clinical studies; risks related to volatile market
and economic conditions; risks related to the impact of public
health epidemics affecting countries or regions in which Cabaletta
has operations or does business, such as COVID-19; Cabaletta’s
ability to retain and recognize the intended incentives conferred
by Orphan Drug Designation and Fast Track Designation for its
product candidates, as applicable; risks related to Cabaletta’s
ability to protect and maintain its intellectual property position;
risks related to fostering and maintaining successful relationships
with Cabaletta’s collaboration and manufacturing partners;
uncertainties related to the initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Cabaletta’s product candidates will not be
successfully developed and/or commercialized; and the risk that the
initial or interim results of preclinical studies or clinical
studies will not be predictive of future results in connection with
future studies. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Cabaletta’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Cabaletta’s most recent annual report on Form 10-K as
well as discussions of potential risks, uncertainties, and other
important factors in Cabaletta’s subsequent filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release, and Cabaletta undertakes
no duty to update this information unless required by law.
Contacts:
Anup MardaChief Financial
Officerinvestors@cabalettabio.com
William GramigStern Investor Relations,
Inc.william.gramig@sternir.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Apr 2024 to May 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From May 2023 to May 2024